Marker Therapeutics Inc (MRKR)

$0.89 -0.05 (-5.47%)
Market Cap 12.21M
Revenue (ttm) 6.59M
Net Income (ttm) -10.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -162.82%
Debt to Equity Ratio 0.00
Volume 144,900
Avg Vol 245,374
Day's Range N/A - N/A
Shares Out 12.94M
Stochastic %K 36%
Beta 1.47
Analysts Strong Sell
Price Target $8.17

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, MS: BCM251, Houston, United States
Awesom69Trade
Awesom69Trade Nov. 14 at 4:55 PM
$MRKR good volumes. Breaking $1 and run soon, imo
0 · Reply
d_rwc
d_rwc Nov. 14 at 3:07 PM
$MRKR With a 50% CR, why isn't this being accelerated to stage 2/3?
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 1:20 PM
$MRKR taking a new position here and selling at 1.20 easy 30% for xmas gifts🎄🎉🎈🎁💵
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 10:56 AM
$MRKR significant reduction in net loss. this is going to be the tailwind.
0 · Reply
TitusPullo1964
TitusPullo1964 Nov. 14 at 9:31 AM
$MRKR Good morning! So, the financing is secured until the third quarter of 2026, which is a very positive sign for 10 months. Is this a risky investment? Well, what investment is risk-free? What matters is that more positive news will follow the already successful trials. We'll see. I'm invested with several thousand shares and will remain so. Good luck to everyone. Greetings from Germany
0 · Reply
Trak2
Trak2 Nov. 14 at 3:38 AM
$MRKR yes, they say they have money till the third quarter of 2026. hopefully, they announce some good data in the next four or five months
0 · Reply
Trak2
Trak2 Nov. 14 at 3:35 AM
$MRKR yes, They say they have money till the third quarter of 2026. hopefully, they announce good data in the next four or five months
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 2:56 AM
$MRKR 18 million in cash! that buys time. should start moving upwards as cash dilution was the issue. good time to add for a small swing...needs $$ for xmas
0 · Reply
WhereAmIGoing
WhereAmIGoing Nov. 14 at 12:43 AM
$MRKR priced in already. The Form 10-Q in which this language appears is dated and filed on August 14, 2025
0 · Reply
d_risk
d_risk Nov. 13 at 10:31 PM
$MRKR - Marker Therapeutics, Inc. - 10Q - Updated Risk Factors MRKR warns that government agency funding shortfalls or shutdowns could delay product development and regulatory processes, potentially harming business operations. #Biotechnology #OperationalRisk #ProductDevelopment #RegulatoryDelays #GovernmentFundingRisk 🟢 Added 🟠 Removed https://d-risk.ai/MRKR/10-Q/2025-11-13
0 · Reply
Latest News on MRKR
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 5 hours ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 5, 2025, 7:30 AM EST - 9 days ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Nov 3, 2025, 9:15 AM EST - 11 days ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Oct 6, 2025, 7:30 AM EDT - 5 weeks ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 12:34 PM EDT - 2 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 3 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 5 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 6 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 6 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 8 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 9 months ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 11 months ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 11 months ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 11 months ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 1 year ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 2 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 2 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

May 4, 2022, 10:30 AM EDT - 3 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 17, 2022, 5:45 PM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Awesom69Trade
Awesom69Trade Nov. 14 at 4:55 PM
$MRKR good volumes. Breaking $1 and run soon, imo
0 · Reply
d_rwc
d_rwc Nov. 14 at 3:07 PM
$MRKR With a 50% CR, why isn't this being accelerated to stage 2/3?
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 1:20 PM
$MRKR taking a new position here and selling at 1.20 easy 30% for xmas gifts🎄🎉🎈🎁💵
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 10:56 AM
$MRKR significant reduction in net loss. this is going to be the tailwind.
0 · Reply
TitusPullo1964
TitusPullo1964 Nov. 14 at 9:31 AM
$MRKR Good morning! So, the financing is secured until the third quarter of 2026, which is a very positive sign for 10 months. Is this a risky investment? Well, what investment is risk-free? What matters is that more positive news will follow the already successful trials. We'll see. I'm invested with several thousand shares and will remain so. Good luck to everyone. Greetings from Germany
0 · Reply
Trak2
Trak2 Nov. 14 at 3:38 AM
$MRKR yes, they say they have money till the third quarter of 2026. hopefully, they announce some good data in the next four or five months
0 · Reply
Trak2
Trak2 Nov. 14 at 3:35 AM
$MRKR yes, They say they have money till the third quarter of 2026. hopefully, they announce good data in the next four or five months
0 · Reply
SimSimBola
SimSimBola Nov. 14 at 2:56 AM
$MRKR 18 million in cash! that buys time. should start moving upwards as cash dilution was the issue. good time to add for a small swing...needs $$ for xmas
0 · Reply
WhereAmIGoing
WhereAmIGoing Nov. 14 at 12:43 AM
$MRKR priced in already. The Form 10-Q in which this language appears is dated and filed on August 14, 2025
0 · Reply
d_risk
d_risk Nov. 13 at 10:31 PM
$MRKR - Marker Therapeutics, Inc. - 10Q - Updated Risk Factors MRKR warns that government agency funding shortfalls or shutdowns could delay product development and regulatory processes, potentially harming business operations. #Biotechnology #OperationalRisk #ProductDevelopment #RegulatoryDelays #GovernmentFundingRisk 🟢 Added 🟠 Removed https://d-risk.ai/MRKR/10-Q/2025-11-13
0 · Reply
SimSimBola
SimSimBola Nov. 13 at 7:31 PM
$MRKR Titus😁
0 · Reply
TitusPullo1964
TitusPullo1964 Nov. 13 at 7:26 AM
$MRKR The next quarterly results are expected to be released on November 13, 2025. The company will also be attending the 67th Annual Meeting of the American Society of Hematology (ASH) and will present results from its ongoing Phase 1 study of MT-601. Let's see what's new.
0 · Reply
TitusPullo1964
TitusPullo1964 Nov. 13 at 7:20 AM
$MRKR I'm still here, yes, something should be coming today.
0 · Reply
birddogsfly
birddogsfly Nov. 12 at 10:06 PM
$MRKR ER tomorrow? Whatever happened to Titus? He was so hopeful it was heartbreaking and then he just disappeared before the action begins.
1 · Reply
SimSimBola
SimSimBola Nov. 12 at 7:31 PM
$MRKR say no to shaving pubic hair
0 · Reply
WhereAmIGoing
WhereAmIGoing Nov. 12 at 4:54 PM
$MRKR
0 · Reply
birddogsfly
birddogsfly Nov. 12 at 4:31 PM
$MRKR purchased my weekly 100 today. Don't buy the ask! Set buys at the bid or a pubic hair above it. Don't feed the bears.
0 · Reply
SimSimBola
SimSimBola Nov. 11 at 1:19 PM
$MRKR
0 · Reply
Viperwilder
Viperwilder Nov. 11 at 10:13 AM
$MRKR Sept 9, 23, Nov 3, looks like a Triple bottom is forming, but not confirmed yes, we need to close above 0.94 and have some volume and it's a confirmed breakout like most of us waiting here
2 · Reply
Awesom69Trade
Awesom69Trade Nov. 11 at 12:36 AM
$MRKR pop to $5+ so we can have a big Thanksgiving!
0 · Reply
JValis
JValis Nov. 11 at 12:24 AM
$MRKR can't buy on revolut. $ATYR Same case. Slowly dying 😬
1 · Reply
jsmith14
jsmith14 Nov. 10 at 8:40 PM
$MRKR looks like a triple bottomed formed
0 · Reply